Lasa Supergenerics Limited (NSE:LASA)
India · Delayed Price · Currency is INR 8.04
-0.20 (-2.43%)
Feb 19, 2026, 3:29 PM IST
Lasa Supergenerics Company Description
Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India.
It offers API bulk drug products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, triciabendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, halquinol, and 2,6-diiodo-4-nitrophenol; and other API products.
The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use, such as potassium iodide.
In addition, it exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Ratnagiri, India.
Lasa Supergenerics Limited
| Country | India |
| Founded | 2016 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 66 |
| CEO | Omkar Herlekar |
Contact Details
Address: Plot no. C-4 Ratnagiri, 415722 India | |
| Phone | 91 77 9888 8188 |
| Website | lasalabs.com |
Stock Details
| Ticker Symbol | LASA |
| Exchange | National Stock Exchange of India |
| Fiscal Year | April - March |
| Reporting Currency | INR |
| ISIN Number | INE670X01014 |
| SIC Code | 2833 |
Key Executives
| Name | Position |
|---|---|
| Dr. Omkar Pravin Herlekar | Chairman and MD |
| Varsha Pravin Joshi | Chief Financial Officer |
| Mitti Jain C.S. | Company Secretary and Compliance Officer |
| Anil Fargade | Senior Accounts Officer |
| Sunil Sitale | Manager of Human Resources and Admin |